College of Public Health, The Ohio State University, Columbus, OH 43210, U.S.A.
Anticancer Res. 2011 Oct;31(10):3279-84.
Concurrent and sequential administration of combinations of budesonide, bexarotene, suberoylanilide hydroxamic acid (SAHA) and atorvastatin were evaluated in A/J mice for prevention of lung tumors initiated by 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol, NNK).
Individual drugs and their combinations were administered for 26 weeks after NNK initiation. For sequential administration, budesonide was given for 21 weeks followed by a second drug.
Alone, budesonide, bexarotene, and SAHA caused a significant decrease in total and large tumors at 21 and 26 weeks. Concurrent treatment with budesonide and bexarotene or SAHA caused a significantly greater decrease in total tumors and large tumors than either drug administered alone. Sequential administration of all combinations (except budesonide/atorvastatin) gave a significant reduction in total and large tumors. Budesonide followed by SAHA and SAHA with atorvastatin yielded a greater reduction in large tumors.
Combinations of drugs demonstrated a greater efficacy in preventing mouse lung tumors than did the individual agents.
布地奈德、贝沙罗汀、丁酸钠和阿托伐他汀联合应用于 A/J 小鼠，评价其对 NNK 引发的肺肿瘤的预防作用。
在 NNK 引发后，单独给予药物及其组合 26 周。对于序贯给药，布地奈德给药 21 周，然后给予第二种药物。
单独给予布地奈德、贝沙罗汀和丁酸钠在 21 周和 26 周时均可显著减少总肿瘤和大肿瘤。布地奈德和贝沙罗汀或丁酸钠联合应用可显著减少总肿瘤和大肿瘤，优于单独应用任一药物。所有联合用药（布地奈德/阿托伐他汀除外）均可显著减少总肿瘤和大肿瘤。布地奈德序贯丁酸钠和丁酸钠联合阿托伐他汀可显著减少大肿瘤。
与单一药物相比，药物联合应用在预防小鼠肺肿瘤方面更有效。
